Glioblastoma (brain tumors): Targeting a rare but deadly disease

While less than 1% of people will be diagnosed with malignant brain tumors, only 1 in 3 will survive 5 years.1

Indoximod may help the immune system outsmart glioblastomas2

NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.3,4


brain-tumor-chart

Learn more about the indoximod study in glioblastoma

 

References

1. National Cancer Institute. SEER stat fact sheets: brain and other nervous system. http://seer.cancer.gov/statfacts/html/brain.html. Accessed October 4, 2015. 2. National Institutes of Health. Study of IDO inhibitor and temozolomide for adult patients with primary malignant brain tumors. http://clinicaltrials.gov/ct2/show/record/NCT02052648. Accessed October 4, 2015. 3. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 4. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.